Ignite Creation Date:
2025-12-24 @ 12:47 PM
Ignite Modification Date:
2025-12-27 @ 9:39 PM
Study NCT ID:
NCT05469061
Status:
UNKNOWN
Last Update Posted:
2022-07-21
First Post:
2022-06-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2021-SR-372
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None